U.S. Oncology Based In-vivo Cro Market Size & Outlook
U.S. oncology based in-vivo cro market, 2018-2030 (US$M)
Related Markets
U.S. oncology based in-vivo cro market highlights
- The U.S. oncology based in-vivo cro market generated a revenue of USD 498.9 million in 2023 and is expected to reach USD 894.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 8.7% from 2024 to 2030.
- In terms of segment, solid tumor was the largest revenue generating indication in 2023.
- Solid Tumor is the most lucrative indication segment registering the fastest growth during the forecast period.
Oncology based in-vivo cro market data book summary
| Market revenue in 2023 | USD 498.9 million |
| Market revenue in 2030 | USD 894.4 million |
| Growth rate | 8.7% (CAGR from 2023 to 2030) |
| Largest segment | Solid tumor |
| Fastest growing segment | Solid Tumor |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Solid Tumor |
| Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Labcorp Holdings Inc, Wuxi AppTec Co Ltd, Evotec SE, Taconic Biosciences, The Jackson Laboratory |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.4% of the global oncology based in-vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. oncology based in-vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 894.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Based In-vivo CRO Market Scope
Oncology Based In-vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. oncology based in-vivo cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based in-vivo cro market will help companies and investors design strategic landscapes.
Solid tumor was the largest segment with a revenue share of 47.2% in 2023. Horizon Databook has segmented the U.S. oncology based in-vivo cro market based on blood cancer, solid tumor covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. forms the largest market for oncology in-vivo CRO market owing to funding provided by the NIH for research and presence of expertise and state-of-the-art infrastructure that is lacking in other regions. Rats and mice are the most commonly used research animals.
According to the statistics published by the People for Ethical Treatment of Animals (PETA), more than 100 million animals were sacrificed in 2014 for medical training, cosmetic testing, experimentation, biology lessons, and drug testing.
In order to ensure that this number is reduced and then number of animals sacrificed for the purpose of research is minimum, regulatory bodies have been set up across the states of the U.S. The United States Department of Agriculture has enlisted various guidelines and goals to ensure animal safety and care to be taken while performing these experiments.
Reasons to subscribe to U.S. oncology based in-vivo cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. oncology based in-vivo cro market databook
-
Our clientele includes a mix of oncology based in-vivo cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. oncology based in-vivo cro market , including forecasts for subscribers. This country databook contains high-level insights into U.S. oncology based in-vivo cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. oncology based in-vivo cro market size, by indication, 2018-2030 (US$M)
U.S. Oncology Based In-vivo CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
